EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

[ 18 F]Fluorodeoxyglucose positron emission tomography ([ 18 F ] FDG PET) Characterizes Neurodegeneration Levels Across the α‐ Synucleinopathy Continuum

Beatrice Orso iD, Ignacio Roura iD, Pietro Mattioli iD, Francesco Famà, Federico Massa iD, Luigi Lorenzini, Andrea Brugnolo, Nicola Girtler, Mattia Losa, Stefano Raffa, Luca Sofia, Monica Roascio iD und 4 weitere

Movement Disorders · 2026-07 · 41 (7) · 1786-1797

DOI: 10.1002/mds.70301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 05.04.2026. Verfasst von Beatrice Orso und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Parkinson Disease, Synucleinopathies, REM Sleep Behavior Disorder. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Istruzione, dell'Università e della Ricerca, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background [ 18 F]Fluorodeoxyglucose positron emission tomography ([ 18 F]FDG PET) represents an endorsed neurodegeneration biomarker in neuronal α‐ synucleinopathies. Idiopathic/isolated rapid eye movement (REM) sleep behavior disorder (iRBD) represents a prodromal stage of such disorders.

Objectives

To assess [ 18 F]FDG PET as a neurodegeneration biomarker, using published brain metabolic disease‐related patterns, and a regional‐based approach, across the prodromal to overt α‐ synucleinopathy continuum.

Methods

We included 83 prodromal subjects with iRBD, comprising non‐converters (n = 56) and converters (n = 27) to an overt α‐ synucleinopathy (either Parkinson's disease [PD] or dementia with Lewy bodies [DLB]) according to the last available follow‐up, and 85 subjects with PD (n = 40) and DLB (n = 45). For comparison, we enrolled a group of healthy subjects (n = 41). Participants underwent brain [ 18 F]FDG PET at baseline. Analysis of covariance was used to test the ability of previously published [ 18 F]FDG PET disease‐related patterns in characterizing neurodegeneration levels along the prodromal to overt α‐ synucleinopathy continuum, and across the motor‐predominant (parkinsonism‐first) and the cognitive‐predominant (dementia‐first) clinical trajectories. We further assessed metabolic changes using a regional‐based approach.

Results

All disease‐related patterns effectively discriminated clinical stages, from prodromal to overt α ‐synucleinopathies, with comparable performance. [ 18 F]FDG PET significantly distinguished all groups along the cognitive‐predominant pathway; whereas in the motor‐predominant pathway, converter patients were not significantly discriminated from non‐converters. Regionally, the inferior parietal, precuneus, and middle frontal areas exhibited the most prominent decrease in [ 18 F]FDG uptake with progression, alongside relative parallel progressive increases in the cerebellum, pons, parahippocampal areas, putamen, and pallidum. Conclusions [ 18 F]FDG PET disease‐related patterns efficiently characterize neurodegeneration from prodromal to overt α ‐synucleinopathy, best assessing the cognitive‐predominant (dementia‐first) pathway. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyParkinson DiseaseSynucleinopathiesREM Sleep Behavior DisorderLewy Body DiseaseBrainHumansFemaleFluorodeoxyglucose F18MaleAgedProdromal SymptomsDisease ProgressionMiddle AgedRadiopharmaceuticalsalpha-SynucleinAged, 80 and overNeurodegenerative Diseases

Stichwörter der Autor:innen

[18F]FDG PETdisease progressionneurodegenerationneuroimagingα‐synucleinopathy

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticalsalpha-Synuclein

Autor:innen und Institutionen

  • Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.
  • Medical Psychology Unit, Department of Medicine, Institute of Neurosciences, University of Barcelona, Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Clinical Neurophysiology, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.
  • Clinical Neurology Unit, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC Location VuMC, Vijre Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.

ORCID-Profile: Beatrice Orso, Ignacio Roura, Pietro Mattioli, Federico Massa, Monica Roascio

Förderung

  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • Ministero della Salute

Zitieren

APA

Orso, B., Roura, I., Mattioli, P., Famà, F., Massa, F., Lorenzini, L., Brugnolo, A., Girtler, N., Losa, M., Raffa, S., Sofia, L., Roascio, M., Arnulfo, G., Morbelli, S., Pardini, M., & Arnaldi, D. (2026). [ 18 F]Fluorodeoxyglucose positron emission tomography ([ 18 F ] FDG PET) Characterizes Neurodegeneration Levels Across the α‐ Synucleinopathy Continuum. Movement Disorders, 41(7), 1786-1797. https://doi.org/10.1002/mds.70301

Vancouver

Orso B, Roura I, Mattioli P, Famà F, Massa F, Lorenzini L, et al. [ 18 F]Fluorodeoxyglucose positron emission tomography ([ 18 F ] FDG PET) Characterizes Neurodegeneration Levels Across the α‐ Synucleinopathy Continuum. Movement Disorders. 2026;41(7):1786-1797. doi:10.1002/mds.70301

BibTeX
@article{Orso2026,
  author = {Orso, Beatrice and Roura, Ignacio and Mattioli, Pietro and Famà, Francesco and Massa, Federico and Lorenzini, Luigi and Brugnolo, Andrea and Girtler, Nicola and Losa, Mattia and Raffa, Stefano and Sofia, Luca and Roascio, Monica and Arnulfo, Gabriele and Morbelli, Silvia and Pardini, Matteo and Arnaldi, Dario},
  title = {[ 18 F]Fluorodeoxyglucose positron emission tomography ([ 18 F ] FDG PET) Characterizes Neurodegeneration Levels Across the α‐ Synucleinopathy Continuum},
  journal = {Movement Disorders},
  year = {2026},
  volume = {41},
  number = {7},
  pages = {1786--1797},
  doi = {10.1002/mds.70301}
}
Kostenlos starten →